Atlas Trials

Spero Therapeutics

22 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Spero Therapeutics

RecordFirmDate
A Study to Characterize Single and Repeat Dose Pharmacokinetics of Tebipenem-Pivoxil-Hydrobromide (TBP-PI-HBr) and Its Major Metabolite (SPR1349) in Healthy Participants (NCT06727136)Spero Therapeutics2024-11-20
A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) (NCT06059846)Spero Therapeutics2023-12-21
A Study to Evaluate the Effect of Co-administration on the Pharmacokinetics of SPR720, Azithromycin, and Ethambutol in Healthy Participants (NCT05966688)Spero Therapeutics2023-08-04
A Study to Assess the Intrapulmonary Pharmacokinetics (PK) of SPR719 by Comparing the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations Following the Oral Administration of Multiple Doses of SPR720 in Healthy Volunteers. (NCT05955586)Spero Therapeutics2023-08-01
A Study to Compare Two Bioanalytical Assays for Tebipenem (NCT05856747)Spero Therapeutics2023-05-04
A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SPR720 as Compared With Placebo for the Treatment of Participants With Mycobacterium Avium Complex (MAC) Pulmonary Disease (NCT05496374)Spero Therapeutics2022-12-14
Phase 1 Study of PK and Safety of SPR206 in Subjects With Various Degrees Of Renal Function (NCT04865393)Spero Therapeutics2021-06-08
Study to Assess the Intrapulmonary Pharmacokinetics of SPR206 in Healthy Volunteers (NCT04868292)Spero Therapeutics2021-06-03
Study to Assess the Intrapulmonary Pharmacokinetics of SPR859 by Comparing the Plasma, Epithelial Lining Fluid (ELF), and Alveolar Macrophages (AM) Concentrations Following the Oral Administration of Five Doses of SPR994 in Healthy, Nonsmoking Volunteers (NCT04710407)Spero Therapeutics2020-12-07
Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease (NCT04553406)Spero Therapeutics2020-12-03
Study of the Absorption, Metabolism, and Excretion of [14C]-Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) Following a Single Oral Dose in Healthy Male Subjects (NCT04625855)Spero Therapeutics2020-09-30
Study to Examine the Effect of Antacid and Omeprazole on the Single-Dose Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects (NCT04368585)Spero Therapeutics2020-07-01
Bioequivalence Study Comparing Two Tablet Formulations of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects (NCT04421885)Spero Therapeutics2020-06-01
Effect of Tebipenem on Normal Human Intestinal Microbiota (NCT04376554)Spero Therapeutics2020-02-10
A Single-Dose, Randomized, Placebo- and Active-Control, Four-Way, Cross-Over Study for the Evaluation of the Effect of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) on the QT/QTc Intervals in Adult Healthy Subjects (NCT04238195)Spero Therapeutics2020-01-19
Phase 1 Study of PK and Safety of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Subjects With Various Degrees Of Renal Function (NCT04178577)Spero Therapeutics2019-12-06
Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) (NCT03788967)Spero Therapeutics2019-06-03
A Study of the Safety, Tolerability, and Pharmacokinetics of SPR720 in Healthy Volunteers (NCT03796910)Spero Therapeutics2018-12-18
Phase 1 Study to Evaluate DDI, PK, Safety, Tolerability of SPR741 (NCT03376529)Spero Therapeutics2017-11-10
Phase 1 Study of Safety, Tolerability and Pharmacokinetics of SPR994 (NCT03395249)Spero Therapeutics2017-10-20

Track Spero Therapeutics automatically

Every clearance here is in the API, with alerts when new ones post.